Oncotelic Therapeutics, Inc. OTLC
0.02 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
0.0152 Day range 0.0166
0.0152 52-week range 0.11
- YTD
- -75.00%
- 1 year
- -81.82%
- Market cap
- 9.15M
- EPS (ttm)
- 0.59
- P/E ratio
- 0.03
- YTD return
- -75.00%
- 1-year return
- -81.82%
- Volume
- 146.29K
- Avg volume
- 347.37K
- Open
- 0.0166
- Previous close
- 0.02
- Day's range
- 0.0152 – 0.0166
- 52-week range
- 0.0152 – 0.11
- Earnings date
- Aug 18, 2023
1Y -0.0845 (-84.50%)
Next earnings
Aug 18, 2023
Expected Aug 18, 2023. Consensus EPS estimate 0.00.
Financials — quick view
OTLC Revenue — quarterly 70.00K
OTLC Net income — quarterly 115.31K
OTLC EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Apr 12, 2024 | Dec 1, 2023 | 0.00 | 0.00 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 18, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
News
Oncotelic Announces PDAOAI Identification of a Four-Gene Liver Cancer Signature 
Oncotelic Keynote to Highlight Partition and Aggregation as a Fundamental Principle for AI Enabled Discovery 
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026 
Oncotelic Therapeutics, Inc. to Present at the OTCQB Virtual Investor Conference on August 6th 
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus) 
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway 
Oncotelic Announces Peer-Reviewed Validation of Deciparticle™ Platform Supporting Clinical Development of Sapu003 
Oncotelic Launches AI-Powered GMP Manufacturing Services Platform at BIO International Convention 2026 
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services 
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Exploration of Nanoparticle, Targeted Drug-Delivery Technologies
Your note
Sign in to keep a note on OTLC — it syncs with the Stock Master app.